Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Flora Growth Corp.’s (NASDAQ: FLGC) Products Ready for New International Markets

Flora Growth Corp. (NASDAQ: FLGC) is entering 2022 with momentum from the past year’s aggressive growth campaign for its global cannabis-derivative brand distribution of pharmaceuticals, cosmetics and nutraceuticals. While the COVID-19 pandemic has had a deleterious effect on the global sustainability agenda, Flora Growth has prioritized value-chain sustainability among each of its brands, acting at a local level to establish products that will have a beneficial effect on communities and the world at large. Flora’s core product, organic cannabis oil, comes from an inherently sustainable process at the company’s cultivation site in central Colombia. “The company recently began filling the initial orders for its Mind Naturals and Awe CBD skincare brands in Spain and Mexico. They expect to begin distribution of medical cannabis products throughout Europe during the coming year thanks to a pathway established through an investment program with European Union GMP partner Hoshi International Inc.,” a recent article reads. “After months of preparation, our products meet all the needs of today’s consumers, and we are ready for new international markets,” Flora Beauty General Manager Andrew Restrepo stated when the Mind Naturals and Awe CBD orders were announced.

To view the full article, visit https://ibn.fm/e3S1T

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Flora Growth Corp. FLGC | Leave a comment

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Builds on 2021 Growth with Plans for 86 Plant-based Store Outlets, Ongoing Educational Efforts in Coming Year

  • Plant-based lifestyle brand builder PlantX Life Inc. offers more than 5,000 plant-based products through meal and indoor plant deliveries, and the company is working through research and development to introduce new product categories in the coming year
  • PlantX is also adding to its physical XMarket store locations, advancing from initial British Columbia and California outlets to new locations in Ontario (Toronto and Ottawa), with further XMarket brand transition under way at stores in the Chicago area of Illinois
  • The company is also preparing to open a new store and e-commerce presence in Tel Aviv, Israel this month as part of its first global endeavor outside of North America     
  • The XMarket physical retail locations have the primary role of enhancing the company’s e-commerce capabilities by acting as fulfillment centers that the company can use to improve its distribution infrastructure and better serve its online customers     
  • PlantX recently announced the election of directors and the appointment of new auditors to shareholders as further development of its strategy for the new year

Consumer trends indicate the demand for plant-based proteins as an alternative to animal products is growing at a tremendous pace, with a CAGR of 9.7 percent anticipated between 2021 and 2028 to produce revenues of $23.4 billion, according to industry analysts at Research and Markets.

“The growth of this market is mainly attributed to the growing demand for protein-rich diet, growing health & wellness trend, increasing consumers’ focus on meat alternatives, growing demand from the food & beverage industry, and various advancements in ingredient technologies such as microencapsulation are the key factors driving the growth of the plant-based protein market,” the report states (https://ibn.fm/Edblk). 

Progressive plant-based lifestyle platform builder PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) marked 2021 as a growth year as it added retail outlets to strengthen its vision of becoming a one-stop shopping and education hub for all plant-based community interests, such as those expressed in the Research and Markets forecast, as PlantX grows toward 86 planned store locations to be opened by the end of this year in support of its e-commerce platform (https://ibn.fm/9em1W).

It’s an ambitious goal for a company still in the beginning phases of its brick-and-mortar openings. PlantX is a Vancouver, British Columbia-based Canadian entity that partnered with chef Matthew Kenney of Matthew Kenney Cuisine to establish the company’s XMarket branded stores last year in British Columbia, Southern California (Los Angeles and San Diego areas), and Ontario (Toronto and Ottawa), with two locations set to rebrand as XMarket in Illinois (Chicago area) as well as a new store opening expected this month in Israel (Tel Aviv).

Each of the physical store locations serve local plant-based communities, but their primary role will be to establish an extensive network of fulfillment centers for PlantX’s e-commerce operations. As the network of XMarket stores grows, the strength of PlantX’s distribution infrastructure will grow as well, enhancing the company’s ability to serve its customers in regions throughout North America and around Israel.

Recently, PlantX made an important announcement – the debut of its innovative XMarket café and store at Hudson’s Bay Rideau in Ottawa — Canada’s capital city in southeast Ontario. The 100 percent plant-based café features carefully-crafted vegan beverages and plant-based food options with ingredients sourced from Ottawa businesses, including local bakery Keepin’ it Vegan (https://ibn.fm/RKhzS).

The company also announced the results of a general meeting of shareholders, including the election of directors and the appointment of new auditors for the ensuing year (https://ibn.fm/vaHKf).

The company’s recent acquisition of plant-based market and e-commerce platform Peter Rubi has provided PlantX its physical store locations in the Chicago area of the United States, which it plans to convert to XMarket locations in the near future (https://ibn.fm/xkruY). Peter Rubi’s warehousing assets will benefit PlantX’s fulfillment and distribution infrastructure in the U.S. Midwest as the company continues to grow.

PlantX became a seller on the Walmart Marketplace last year, offering more than 500-plant based grocery products through the global retailer’s massive reach to consumers. Overall, PlantX offers customers across North America more than 5,000 plant-based products through meal and indoor plant deliveries, and the company is preparing to expand its product lines to include cosmetics, clothing, personal care and its own water brand, underscoring the importance of a strong fulfillment infrastructure.

The company recently announced the expansion of its online operations to include discounts for shoppers who subscribe for recurring service, and it is contracting with social media “micro-influencers” to help build the PlantX brand. 

Its website’s educational efforts include community-focused information shared through a weekly podcast, YouTube channel and blog. 

Bloomberg Intelligence analysts valued the overall global market for plant-based foods and products, including the plant-based protein market mentioned earlier, at $29.4 billion in 2020. The analysts predicted revenues will exceed $162 billion by 2030, which would be an astronomical increase of 451 percent (https://ibn.fm/DBeYw).

For more information, visit the company’s websites at www.PlantX.comwww.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in PlantX Life Inc. PLTXF | Leave a comment

FingerMotion Inc. (NASDAQ: FNGR) Q3 Financial Report Notes Record Profit Growth, Ongoing Efforts to Build SMS, Big Data Services

  • U.S.-based communications technology brand FingerMotion is building its profits as it focuses on services for China’s world-leading, mobile-connected population
  • FingerMotion recently reported its financial statement for the Q3 quarter ending Nov. 30, noting gross profits at a record $967,075
  • The profits report was 56 percent higher than the same period during the previous year, driven primarily by the company’s Telecommunications Products and Services business
  • FingerMotion’s Telecommunications Products and Services revenues grew 580 percent YOY despite a slowing trend for SMS services as the company shifted resources to the company’s collaboration with China Mobile in the country’s Fujian province for 5G-related SMS products

Evolving communications and big data technology company FingerMotion (NASDAQ: FNGR), is entering 2022 with record profitability and continued growth of its gross margins. 

“We expect this trend in gross margins to continue, and revenue should ramp as the insurtech business starts to unfold,” CEO Martin Shen stated in conjunction with the company’s announcement Jan. 18 of its financial profile for the third quarter ended Nov. 30 (https://ibn.fm/ypswa). “During the past quarter the company announced the formation of two new brands in order to provide mobile device protection in China. Beta testing is underway and could start contributing to revenue in the current quarter. The company anticipates this could represent a significant revenue stream in the next fiscal year.”

FingerMotion reported its gross profit reached a new record of $967,075 during the quarter, driven by revenues of $5.9 million. That marked a 21 percent increase year-over-year in the revenue report, with the gross profit 56 percent higher YOY. 

The bulk of the revenue optimism came from the company’s Telecommunications Products and Services business, which grew 580 percent ($2.8 million) over the previous year’s Q3 report. 

The company’s Big Data analysis division, Sapientus, reported its first revenues last year and is expected to eventually be the leading revenue generator for FingerMotion as it enters the market for insurtech services. The division did not report any revenue for Q3, but the company continues to devote “considerable time … on continuing discussions with Pacific Life Re, the global life reinsurance company” that was the first company to contract with FingerMotion for big data services, Shen stated. 

FingerMotion is a China-focused company specializing in mobile technology services. The Asian nation contains nearly 1.5 billion mobile users and analysts at Reportlinker.com anticipate that mobile engagement in China will continue to grow in the years to come, achieving a CAGR of 44.7 percent between 2020 and 2027 for revenues of $22.4 billion by the end of the forecast period. 

That’s about a quarter of the analysts’ entire global forecast for the period. 

Shen states FingerMotion is particularly focused on the company’s collaboration with China Mobile in the country’s Fujian province. China Mobile Fujian has about 30 million or more online subscribers, which is about 70 percent of the market share in the province, according to an announcement by the company last year (https://ibn.fm/PkXvC).

The mutual effort between the two companies relates to the buildup of 5G wireless network services in China, and the resources of FingerMotion SMS subsidiary JiuGe.

“During the quarter we were aggressive in rolling out our collaboration with China Mobile in the Fujian province. We had to reallocate our resources into telecom which slowed the spectacular revenue growth in SMS that we had seen in the past,” Shen stated, noting that SMS texting services and multimedia MMS audio and video services have been the reason for the Telecommunications Products and Services business sector’s success. 

FingerMotion reported it had $1,116,448 in cash, a working capital surplus of $5,489,655 and a positive shareholders equity of $5,667,780 at the end of the quarter.  

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in FingerMotion Inc. FNGR | Leave a comment

Nemaura Medical Inc. (NASDAQ: NMRD) Firmly Positioned in Growing Diabetes Tech Market With Recent CGM Shipment to UK Licensee

  • Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS 
  • Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetes
  • NMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose monitor
  • Company recently completed initial shipment to UK licensee

While most medical technology businesses faced COVID-19-related restrictions (https://ibn.fm/NJbOa), Nemaura Medical (NASDAQ: NMRD), a medical technology company that develops affordable diagnostic and digital tools for diabetes management, is favorably positioned in the rapidly growing diabetes tech market with sugarBEAT(R) – a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed to help diabetes patients manage glucose levels. 

Diabetes is a significant concern in the United States, according to a report released by the Center for Disease Control (“CDC”) that provides statistics across ethnicities, ages, education levels, and regions (https://ibn.fm/Ch1HI). According to the report, 34.2 million Americans – roughly 10 percent – have diabetes, and approximately one in three have pre-diabetes. 

“CDC is working to reverse the epidemic by helping to identify people with pre-diabetes, prevent type 2 diabetes and diabetes complications, and improve the health of all people with diabetes,” reads the report. “Through the National DPP’s evidence-based, affordable lifestyle change program, adults with pre-diabetes learn to make healthy changes that can cut their risk of type 2 diabetes by as much as 58% (71% for those over 60 years).”

Controlling insulin is an essential part of the lifestyle changes required to manage and prevent diabetes, according to the US National Institute of Health (“NIH”) (https://ibn.fm/z5jJe). Accordingly, the medtech industry has grown considerably to meet the demand for insulin-monitoring equipment such as insulin pumps and CGM devices. While most businesses faced severe business restraints in 2021, the diabetes tech space had an eventful year with highlights that included climbing user numbers, expansion of coverage for glucose monitoring devices by the Centers for Medicare & Medicaid Services (“CMS”), and bullish analyst projections that forecast increased adoption of diabetes tech devices in 2022 and beyond. 

NMRD is currently in the process of commercializing its sugarBEAT(R) non-invasive, flexible, and affordable CGM device. With actionable insights from real-time glucose monitoring, sugarBEAT(R) is designed to help diabetic and pre-diabetic people prevent, manage, and reverse diabetes symptoms. As part of its marketing strategy, NMRD recently completed an initial shipment of sugarBEAT(R) devices to MySugarWatch Limited, its UK licensee. MySugarWatch Limited intends to market sugarBEAT(R) via a subscription-based diabetes coaching and management service that targets over 4.9 million diabetics and 13.6 million people with an increased risk of contracting Type 2 diabetes in the UK (https://ibn.fm/WxD9P).

“This initial shipment of sugarBEAT(R) CGM devices to our UK licensee allows the Company to now recognize revenue for the first time in our corporate history and is a true milestone in our development and growth,” said Nemaura CEO, Dr. Faz Chowdhury. “Starting in the UK, patients with Type 2 diabetes can now benefit from a less invasive glucose monitoring option that should improve patient lifestyle, adherence, and outcome.”

Founded in 2011, NMRD initially developed a single platform technology to measure blood markers at the skin’s surface. The Company has since evolved into the wearables space at the intersection of global diabetes, pre-diabetes, and weight loss device markets. With diabetes and obesity on the rise, NMRD is dedicated to addressing the growing need for flexible, affordable glucose monitoring solutions that help prevent, manage, and reverse diabetes and pre-diabetic conditions. 

For more information, visit the company websites at www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Nemaura Medical Inc. NMRD | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview

Lexaria Bioscience (NASDAQ: LEXX) CEO and chair Chris Bunka is the guest on a recent episode of the EDGE podcast. Hosted by entrepreneur and angel investor Brandon C. White, the EDGE is a podcast series focused on providing a playbook for business owners that takes a look at the inner game of building a successful business and giving listeners the edge to become smarter, healthier and richer. Lexaria Bioscience is a global innovator in drug-delivery platforms. During the interview, Bunka shared his background and the journey that led him to Lexaria. He also talked about Lexaria’s business model and the company’s focus on improving the delivery of active pharmaceutical ingredients, vitamins and minerals. In addition, he discussed Lexaria’s ongoing efforts to leverage its innovative drug-delivery platform to improve the effectiveness of orally delivered compounds. “Lexaria Bioscience is a tech company, and we provide really, really interesting solutions to the pharmaceutical industry, as well as nutraceuticals and even delivery of beneficial vitamins and minerals in foods,” said Lexaria Bioscience CEO and chair Chris Bunka in the podcast. “Our technology is all about enabling a much higher fraction and a much smoother delivery of the beneficial substances in the foods you eat and in the drugs you take and, quite frankly, getting them into your bloodstream. With a lot of these compounds and drugs, the vast majority of what you eat or swallow ends up in the toilet, and that’s no good. So we can fix that.”

To view the full interview, visit https://ibn.fm/153ow 

To view the full press release, visit https://ibn.fm/9qTYO

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by 5 to 10 times as well as reduce time of onset from one to two hours to minutes and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs; nonsteroidal, anti-inflammatory drugs (“NSAIDs”); and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs Following Independent Review Board Approval

  • Lexaria received independent review board approval for its HYPER-H21-4 human clinical study for hypertension treatment
  • The stage is also set for other R&D programs for the 2022 calendar year, including HOR-A22-1, DEM-A22-1, RHEUM-A22-1 and DIAB-A22-1
  • All of these 2022 R&D programs are fully funded, with Lexaria having raised approximately $15 million over the 2021 calendar year
  • Lexaria believes that these programs will build significant value for its stakeholders and pursue policies for substantial improvements to human health

In late 2021, Lexaria Bioscience (NASDAQ: LEXX) announced several new and ongoing R&D programs for its patented DehydraTECH(TM) technology. While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”), noted that Lexaria would continue to see significant milestones in utilizing DehydraTECH-CBD, focusing on heart disease and hypertension.

“Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” noted Mr. Bunka.

“We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” he added (https://ibn.fm/0HA7M).

It received independent review board approval in what marks a significant milestone for its 2022 R&D program. The approval comes in less than two months after Lexaria announced that it was readying the study protocols for its HYPER-H21-4 study, its fourth recent human clinical study, and its most ambitious one yet (https://ibn.fm/aurm0).

The approval sets the stage for the HYPER-H21-4 study that could define Lexaria’s future. HOR-A22-1 study, scheduled to start in April 2022, will evaluate DehydraTECH’s ability to enhance the delivery characteristics of estrogen. DEM-A22-1, expected to begin in July 2022, will evaluate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia.

Lexaria also plans to execute on the RHEUM-A22-1 and DIAB-A22-1 studies, scheduled for October and November, respectively, in a move that is intended to build significant value for all its stakeholders while also pursuing policies for substantial improvements to human health.

All the R&D for the 2022 calendar year is fully funded, having raised approximately $15 million in funding over the 2021 calendar year. Lexaria is confident that data from the studies will support the company’s plans to enter regulatory pathways, which, it anticipates, will result in the regulatory approval to use DehydraTECH-CBD for the treatment of hypertension and possibly other types of cardiovascular disease.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

SRAX Inc. (NASDAQ: SRAX) Appears to Be on a Hot Streak; Announced Revenue Guidance for 2022 Expecting Another Period of Outstanding Performance

  • SRAX’s performance goes from strength to strength; company announced revenue guidance expecting revenues of $11.5 million for the first quarter and full-year revenues of $46M – $48M.
  • Company’s SaaS platform Sequire expected to continue to drive growth and remain instrumental to performance. 
  • As go-to data provider for investors and public companies, SRAX stays committed to innovating on product, sales, and marketing, which all translates into increased revenue.

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, has announced revenue guidance for 2022, anticipating another strong period ahead. The company expects revenues of $11.5 million for the first quarter, a 111% increase over Q1 2021 revenue. The full-year revenues are expected to be $46M – $48M, an increase of 46% – 52% over 2021 unaudited revenue of approximately $31.5M. In addition, the company announced that the Q4 2021 booking meets expectations (https://ibn.fm/PJKY8).

With solutions built to bring clarity and make the digital space more transparent, SRAX aims to deliver unbiased data and reveal analytics for companies to manage ROI from investor relations programs and corporate communication firms. The company’s growth remains closely linked to Sequire, its SaaS platform. Last year the platform grew both in subscribers and functionality, resulting in considerable revenue growth and customer renewals. This year Sequire has a number of significant releases that will continue to enhance the platform’s value. 

Sequire’s success is driven by its focus on delivering solutions that solve important pain points for public companies. To stay competitive in today’s environment, companies need to better communicate with their shareholders and the broader investment community. As a data analytics platform designed for public companies to track essential data, SRAX provides unique opportunities for investors and public companies to connect and communicate through its Sequire SaaS platform. 

Sequire provides users with data that help them understand market activity and develop insights to engage their investor base. With this platform, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. 

SRAX has also expanded its model to include additional value-added services from the investor relations space, such as their preeminent industry conferences. The company owns LD Micro, a respected conference provider targeted at small and micro-cap markets.

“Our team did excellent work in 2021, meeting and exceeding our guidance. The nature of our annual contracts provides us exceptional visibility into revenue,” said Christopher Miglino, Founder and CEO of SRAX. “We are projecting that we will have our largest quarter ever in Q1 of 2022. With an acceleration in sales at the end of Q4, we are very comfortable in providing a full-year, 2022 guidance of $46-$48M,” added Miglino.

SRAX has seen its financial performance go from strength to strength over the past year, with recently reported results revealing exceptional revenue growth. Its remarkable performance and growth trajectory appear to have contributed to the increased investors’ interest, with several hedge funds and other institutional players adding to their stakes in the company (https://ibn.fm/DPMN0). 

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in SRAX, Inc. SRAX | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor 2022 Top Picks Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate in the Virtual Investor 2022 Top Picks Conference at 11:00 a.m. ET on Wednesday, Jan. 26, 2022. As part of the virtual event, the company will provide a corporate presentation followed by an interactive Q&A session. In addition to the moderated portion, investors and attendees will have the opportunity to submit questions live during the event or in advance of the conference via www.VirtualInvestorCo.com. A live video webcast of the presentation will be available on the company’s website, with a webcast replay available two hours following the live presentation and accessible for one year.

To view the full press release, visit https://ibn.fm/rgfBo

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) Launches New YouTube Series – ‘Medically Speaking’

PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced the launch of its new YouTube series entitled “Medically Speaking,” designed to enhance plant-based education and equip consumers with the necessary knowledge to achieve their plant-based goals. The new series will center around informative conversations with the PlantX medical advisory board on plant-based topics. Beyond providing evidence-based information to clarify potential questions and knowledge gaps in the plant-based space, Medically Speaking also aims to offer creative solutions to overcoming plant-based challenges as approved and discussed by trusted health care professionals. “We have seen a tremendous global shift to plant-based diets in recent years and this trend continues to rise,” said PlantX Founder Sean Dollinger. “As the interest in plant-based diets increases, so does the need and demand for engaging plant-based educational opportunities. Medically Speaking was created as a dynamic and evidence-based educational tool that can explain plant-based myths and misinformation and empower people to overcome barriers to change.”

To view the full press release, visit https://ibn.fm/nfmKW

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 5,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s investor website at https://Investor.PlantX.com and its YouTube channel.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in PlantX Life Inc. PLTXF | Leave a comment

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) to Participate in Innovations and Advancements in the CBD Market Webinar

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables and services to the worldwide food and beverage, biotherapeutics and personal wellness industries, among others, today announced its participation in the Jan. 20, 2022, Innovations and Advancements in the CBD Market webinar. The real-time, interactive “fireside chat,” sponsored by FORCE Family Office, will feature three companies that have released or are about to release important, innovative products and services and/or advancements in the CBD space. Pressure BioSciences, which is planning for a mid-2022 release of its revolutionary Ultra Shear Technology(TM) (“UST”(TM)) platform for the preparation of water soluble, long-term stable, highly bioavailable nanoemulsions of oil and water (e.g., CBD oil and water), announced that its founder and CEO Richard T. Schumacher will serve as a panel participant in the upcoming webinar. Interested parties should visit https://ibn.fm/pcP2J for details and to register for the event.

To view the full press release, visit https://ibn.fm/8Kdsx

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Pressure BioSciences Inc. PBIO | Leave a comment